RxSight, Inc. (RXST) stock
RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value
$5.30−0.02 (-0.38%)
Close on Nov 16, 2026Market cap $220.44MP/E –Yield –
RxSight price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
RxSight's price to sales ratio was 1.7× on Nov 11, 2026, against 3.3× a year earlier. Over the last 5 years it ranged from 1.6× to 22.1×, with a median of 10.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.7× | −1.3 |
| 2025 | Dec 31, 2025 | 3.0× | −7.8 |
| 2024 | Dec 31, 2024 | 10.8× | −8.1 |
| 2023 | Dec 29, 2023 | 18.9× | +10.4 |
| 2022 | Dec 30, 2022 | 8.5× | −7.6 |
| 2021 | Dec 31, 2021 | 16.1× | – |
See a number that looks wrong?